Pharma AI Tracker

CSL announced a collaboration with AWS to bring AI and cloud technology into research and clinical development. The release says the work aims to link lab and computational work more closely and to cut manual effort in protocol authoring, clinical data handling and regulatory submissions, while keeping data governance, traceability and inspection readiness. It names AWS as the principal AI and cloud provider, including services such as Amazon Bedrock.

Partners: Amazon Web Services

A text-to-SQL agent built by Novo's Rare Disease Insights & Analytics team that answers plain-language business questions from claims and prescription data.

Partners: Dataiku

Two Agentforce agents: SEIMEI condenses clinical literature and field conversation notes into insights, and AIMI drafts cited answers to healthcare professionals' medical questions for staff to review.

Partners: Salesforce

Otsuka Holdings' Integrated Report 2026 says technology validation has started to expand the Cysteinomix drug discovery platform using generative AI. In the same report, Taiho Pharmaceutical's Tsukuba discovery division says it is working to introduce robotics and AI in the search for drug targets and compound design while expanding Cysteinomix.

Otsuka Holdings' Integrated Report 2026 states that Astex is using a proprietary dataset of more than 19,000 protein-ligand complexes to develop computational co-folding capabilities called AstexFold and generative AI models for fragment-based and structure-based drug design. The report also mentions the Pyramid platform integrating AI/ML methods. This is company self-reported, and the report does not state a deployment stage.

Takeda is deploying Weave Bio's AI regulatory-writing platform across 14 programs. Use started with IND drafting and has grown to health-authority question responses.

Partners: Weave Bio

Vendor blog recapping a Roche talk: ThoughtSpot says Roche scaled to 500 active users of ThoughtSpot's Spotter AI analytics agent within a year, and has 40,000+ ThoughtSpot users overall.

Partners: ThoughtSpot

Veeva announced that Regeneron has committed to Veeva Vault CRM globally. Veeva says Regeneron's plan is to generate Commercial Evidence via AI-powered field engagement.

Partners: Veeva Systems

Hengrui's 2026 half-year report says the company uses an integrated data-analysis platform to read clinical demand and uses AI tools to deliver medical information through personalized academic communication, in order to improve prescription conversion, with compliance traceability across the process.

UiPath announced that Merck KGaA, Darmstadt, Germany is building a program for agentic software testing on UiPath Test Cloud, applying AI agents, automation and human oversight across the software testing lifecycle.

Partners: UiPath

UCB says it worked with MPIRIQ to explore AI-supported identification and referral of patients with suspected axial spondyloarthritis, and that the teams evaluated a referral pathway that uses AI.

Partners: MPIRIQ

UCB says IB Lab FLAMINGO, an AI platform that was originally a UCB initiative, detects vertebral fractures on routine CT scans and is already validated across European health systems. The article says UCB and ImageBiopsy Lab designed and validated a downstream osteoporosis care pathway for patients the tool identifies.

Partners: ImageBiopsy Lab

Novo named AWS its preferred cloud and strategic AI partner. It plans to use Amazon Bio Discovery for target and therapy design and Bedrock AgentCore for AI agents across operations.

Partners: AWS

AstraZeneca authors describe Research Assistant, an internal LLM tool for exploring biomedical questions, and share lessons from running it at scale in R&D.

Awarathon says Sun Pharma used its AI-powered roleplay assessments and AI-enabled reports to train medical representatives, starting with two divisions at pilot stage and then rolling the platform out across all India business verticals, with teams in South Africa, Bangladesh and Nepal also adopting it.

Partners: Awarathon

Novo will use H1's AI-powered data to improve trial design, site selection and enrollment. H1 also takes rights to advance Novo's in-house StudyHub platform.

Partners: H1

On its Q2 2026 earnings call Pfizer said AI is already lowering manufacturing costs and improving yields.

Uncountable announced that Merck KGaA, Darmstadt, Germany selected its platform to digitalize its central analytical laboratories; Uncountable says the solution will improve data access to enable ML- and LLM-powered use cases.

Partners: Uncountable

In its second-quarter 2026 results, Alnylam said it had announced a collaboration with a large health care system in California to support that system's DETECT-ATTR study. The study evaluates Invision Precision Cardiac Amyloid, described as an AI-enabled, FDA-cleared echocardiography screening approach for cardiac amyloidosis.

In the same results release, Alnylam said it had expanded its strategic partnership with Komodo Health to scale Marmot, which Alnylam describes as Komodo's analytics AI platform, across key enterprise functions at Alnylam.

Partners: Komodo Health

Evinova announced a multi-year collaboration under which Merck KGaA, Darmstadt, Germany will adopt its AI-native platform across study design, document authoring and downstream automation in clinical development.

Partners: Evinova

Novartis says its teams use AI-enhanced analytics to surface early risk signals across trial supply, monitoring and recruitment and to recommend next-best actions.

Novartis says generative AI can create well-structured first drafts of clinical and regulatory documents from approved sources, which Novartis experts then review and refine.

Novartis says that with generative approaches its teams can propose new molecular structures informed by protein information and prior chemistry and optimize multiple properties in parallel.

Cognizant says Novartis selected it for a five-year, AI-enabled integrated IT operations engagement using agentic AI.

Partners: Cognizant